Japan Approves Eisai-Abbott Drug Humira For Two More Indications
This article was originally published in PharmAsia News
Japan's drug regulator gave its approval of Eisai and Abbott Japan's Humira (adalimumab) for two additional indications, including Crohn's disease
You may also be interested in...
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.